Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | SQLE | Q14534 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120742 | 1.00 | KMT2A (0.42) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL121342 | 0.99 | KMT2A (0.41) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL5857338 | 0.99 | KMT2A (0.44) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL5857342 | 0.99 | KMT2A (0.44) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL121994 | 0.99 | KMT2A (0.41) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL123153 | 0.97 | KMT2A (0.43) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL122720 | 0.97 | KMT2A (0.43) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL123154 | 0.97 | KMT2A (0.43) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL474147 | 0.95 | KMT2A (0.43) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL474145 | 0.95 | KMT2A (0.43) | KMT2AALOX15MEN1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-08-09 | — | — | US | claimed |
| EP-2424568-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | University Of Kentucky Research Foundation (US) | 2012-03-07 | — | — | EP | claimed |
| US-7879344-B2 | contains antiitch agent; for use in wipes and absorbent articles, and transdermal patches | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2011-02-01 | — | — | US | claimed |
| WO-2010126501-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-04 | — | — | WO | claimed |
| EP-2040693-A2 | TRANSDERMAL DELIVERY OF OLEOCANTHAL FOR RELIEF OF INFLAMMATION | Kimberly-Clark Worldwide, Inc. (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2008001240-A2 | TRANSDERMAL DELIVERY OF OLEOCANTHAL FOR RELIEF OF INFLAMMATION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-01-03 | — | — | WO | claimed |
| US-20080003273-A1 | Transdermal Delivery of Oleocanthal for Relief of Inflammation | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-01-03 | — | — | US | claimed |
| EP-0813879-B1 | Drug administration composition for iontophoresis | HISAMITSU PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | claimed |
| US-12636309-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | ADORA ANIMAL HEALTH CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-12636308-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | ADORA ANIMAL HEALTH CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250281393-A1 | BODY CAVITY GEL | CS MEDICA A/S (DK) | 2025-09-11 | — | — | US | disclosed |
| US-20250249030-A1 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | ADORA LIFE SCIENCE, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250249031-A1 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | ADORA LIFE SCIENCE, INC. | 2025-08-07 | — | — | US | disclosed |
| EP-4580751-A2 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | Adora Animal Health Corporation (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-0989845-A1 | TOPICAL ADMINISTRATION OF CATECHOLAMINES AND RELATED COMPOUNDS TO SUBCUTANEOUS MUSCLE TISSUE USING PERCUTANEOUS PENETRATION ENHANCERS | PERRICONE, Nicholas V (US) | 2000-04-05 | — | — | EP | disclosed |
| US-5908400-A | DRUG DELIVERY | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1999-06-01 | — | — | US | disclosed |
| US-5879690-A | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers | N.V. PERRICONE LLC | 1999-03-09 | — | — | US | disclosed |
| WO-1998050014-A1 | TOPICAL ADMINISTRATION OF CATECHOLAMINES AND RELATED COMPOUNDS TO SUBCUTANEOUS MUSCLE TISSUE USING PERCUTANEOUS PENETRATION ENHANCERS | PERRICONE NICHOLAS V (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0813887-A2 | A device structure for iontophoresis | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 1997-12-29 | — | — | EP | disclosed |
| EP-0813879-A2 | Drug administration composition for iontophoresis | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 1997-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080003273-A1 | Transdermal Delivery of Oleocanthal for Relief of Inflammation | OXER1, OSBP, OXGR1 | KMT2A 4154/4885ALOX15 52/4885MEN1 4874/4885 |
| US-12636308-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | FUT6, CD44, CSGALNACT1 | KMT2A 4373/4885ALOX15 120/4885MEN1 4842/4885 |
| US-12636309-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | CD44, FUT8, FUT6 | KMT2A 3811/4885ALOX15 2296/4885MEN1 3690/4885 |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | CNR2, CNR1, FAAH | KMT2A 3922/4885ALOX15 273/4885MEN1 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.